A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses ove...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-08-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1001028&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527142687440896 |
|---|---|
| author | Laura M Walker Melissa D Simek Frances Priddy Johannes S Gach Denise Wagner Michael B Zwick Sanjay K Phogat Pascal Poignard Dennis R Burton |
| author_facet | Laura M Walker Melissa D Simek Frances Priddy Johannes S Gach Denise Wagner Michael B Zwick Sanjay K Phogat Pascal Poignard Dennis R Burton |
| author_sort | Laura M Walker |
| collection | DOAJ |
| description | A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most donors through a limited number of specificities (1-2 per donor). The major targets recognized are an epitope defined by the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera. |
| format | Article |
| id | doaj-art-f2544dd28dca4c528b05e84427b0f5fa |
| institution | Kabale University |
| issn | 1553-7366 1553-7374 |
| language | English |
| publishDate | 2010-08-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj-art-f2544dd28dca4c528b05e84427b0f5fa2025-01-16T05:31:02ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742010-08-0168e100102810.1371/journal.ppat.1001028A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Laura M WalkerMelissa D SimekFrances PriddyJohannes S GachDenise WagnerMichael B ZwickSanjay K PhogatPascal PoignardDennis R BurtonA protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most donors through a limited number of specificities (1-2 per donor). The major targets recognized are an epitope defined by the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera.https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1001028&type=printable |
| spellingShingle | Laura M Walker Melissa D Simek Frances Priddy Johannes S Gach Denise Wagner Michael B Zwick Sanjay K Phogat Pascal Poignard Dennis R Burton A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathogens |
| title | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. |
| title_full | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. |
| title_fullStr | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. |
| title_full_unstemmed | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. |
| title_short | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. |
| title_sort | limited number of antibody specificities mediate broad and potent serum neutralization in selected hiv 1 infected individuals |
| url | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1001028&type=printable |
| work_keys_str_mv | AT lauramwalker alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT melissadsimek alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT francespriddy alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT johannessgach alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT denisewagner alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT michaelbzwick alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT sanjaykphogat alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT pascalpoignard alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT dennisrburton alimitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT lauramwalker limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT melissadsimek limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT francespriddy limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT johannessgach limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT denisewagner limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT michaelbzwick limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT sanjaykphogat limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT pascalpoignard limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals AT dennisrburton limitednumberofantibodyspecificitiesmediatebroadandpotentserumneutralizationinselectedhiv1infectedindividuals |